Joint Session of the ESR and EORTC
ESR/EORTC - Holistic evaluation of cancer patients: influence of non-cancer-related factors
Lectures
1
Chairperson's introduction
02:00Frédéric Lecouvet, Brussels / BE
2
Geriatric oncology: moving the needle towards precision oncology for older adults with cancer
20:00Nicolo Battisti, London / UK
3
Impact of body composition on survival in pancreatic cancer
20:00Mario Ghosn, Créteil / FR
4
Opportunistic evaluation of body composition in cancer patients: association with therapy-related toxicity
20:00Stefania Rizzo, Lugano / CH
5
Beyond cancer: alternative role of PET/CT in oncology
20:00Egesta Lopci, Rozzano / IT
6
Panel discussion
08:00Panel discussion
2 min
Chairperson's introduction
Frédéric Lecouvet, Brussels / Belgium
20 min
Geriatric oncology: moving the needle towards precision oncology for older adults with cancer
Nicolo Battisti, London / United Kingdom
- To learn about the challenges of managing cancer in older adults.
- To appreciate the benefits of comprehensive geriatric assessment for older adults with cancer.
- To understand the importance of broader multidisciplinary care input for older adults with cancer.
20 min
Impact of body composition on survival in pancreatic cancer
Mario Ghosn, Créteil / France
- To learn about how body composition is currently assessed and the role of imaging.
- To appreciate the difficulties in body composition assessments and the need for robust objective measures.
- To understand the impact of body composition on treatment strategies in pancreatic cancer.
20 min
Opportunistic evaluation of body composition in cancer patients: association with therapy-related toxicity
Stefania Rizzo, Lugano / Switzerland
- To learn about how body composition is currently assessed in cancer patients and the role of imaging.
- To appreciate the effects of treatment toxicity on body composition.
- To understand the impact of treatment-related toxicity on patient outcome as a result of altered body composition.
20 min
Beyond cancer: alternative role of PET/CT in oncology
Egesta Lopci, Rozzano / Italy
- To learn about how PET/CT is currently used in oncological patients beyond cancer therapy.
- To appreciate the strengths and limitations of PET/CT in treatment-induced body modifications.
- To understand how we should incorporate PET/CT assessments reporting findings beyond cancer in oncology.
8 min
Panel discussion